News

Altamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid Event

Hamilton, Bermuda, Nov. 10, 2022 (GLOBE NEWSWIRE) -- • TIDES Europe Event will be held on November 16-18, 2022, in…

2 years ago

RespireRx Pharmaceuticals Inc. Announces that Jeff Margolis, the Company’s CFO is presenting at the Investor Summit Q4

Glen Rock, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in…

2 years ago

Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update

--FemaSeed® de novo trial enrollment accelerates with strategic trial design update to focus on male factor infertility-- --Company remains on…

2 years ago

Yield10 Bioscience Begins Winter 2022/2023 Field Test and Seed Production Program

-Advancing development of herbicide tolerant Camelina- -Building commercial seed inventory available to growers in 2023 and beyond- WOBURN, Mass., Nov.…

2 years ago

Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer’s Disease

MIAMI, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing…

2 years ago

Healthcare Triangle, Inc (HCTI) Reports Results for the Third Quarter of 2022

PLEASANTON, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc (HCTI), a leading provider of cloud and digital transformation, managed…

2 years ago

Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates

- Topline data from Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency on track for the fourth quarter of…

2 years ago

Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and…

2 years ago